EIC Healthcare Investor Day — Paris, 6 October 2025

On 6 October the European Innovation Council partnered with EuroQuity, the matchmaking platform operated by Bpifrance, to run the EIC Healthcare Investor Day in Paris. The event brought together investors, corporates and business partners to see pitches from 23 companies from the EIC Accelerator portfolio. Organisers reported more than 250 one-on-one meetings and roughly 150 attendees. The day blended curated pitching sessions with prearranged investor meetings aimed at accelerating fundraising and partnership conversations for mission-driven health technologies.

Event format, scale and participants

The Investor Day was structured around short, investor-focused pitches from EIC-backed companies followed by matchmaking slots. A jury of specialised investors and corporate partners helped select the presenting companies. The event emphasised direct introductions rather than broad conference networking. That approach can increase signal-to-noise for founders and investors but does not guarantee follow-on financing. Organisers did not publish conversion metrics for actual investments arising from the meetings.

Who selected the companies

A jury composed of investor representatives led the selection. It included teams from leading European venture funds and corporate innovation units. Listing the jury underscores the degree of investor engagement and the calibre of potential co-investors the presenting companies were exposed to.

Three companies singled out at the event

Organisers recognised three companies for standout pitches. Each operates in a different healthcare sub-sector and is further along because of EIC Accelerator backing. Below we summarise the companies, why investors found them interesting and the key technical or market considerations to watch.

Chipiron (France) — ultra-low-field MRI for broader access

Chipiron is developing a new generation of lightweight, low-cost, full-body MRI machines operating at ultra-low magnetic fields. The company frames its mission as increasing MRI accessibility for screening and diagnostics at scale. Chipiron said participation in curated investor events accelerated its transition from scientific validation toward market readiness and helped it find investors who understand long development cycles and regulatory complexity.

Chipiron CEO Evan Kervella said the Investor Day was catalytic for exposure and credibility and highlighted the value of connecting with deep-tech and life science investors familiar with long development and regulatory cycles.

StarTric (Italy) — TriClover, a transcatheter repair device for the tricuspid valve

StarTric is developing TriClover, a minimally invasive device intended to replicate the Clover surgical edge-to-edge technique for tricuspid valve repair using a transfemoral transcatheter approach. The firm positions TriClover as a device designed specifically for tricuspid anatomy rather than an adaptation of mitral technologies. The company highlighted a large untreated patient pool because open-heart surgery is too risky for most people with severe tricuspid regurgitation.

Eugenio Passanante, StarTric co-founder and CFO, said the Investor Day helped re-engage contacts and open new conversations ahead of a planned fundraising round. He also emphasised the broader ecosystem value of cross-border investor connections for technologies with global potential.

Amadix (Spain) — non-invasive multimodal machine learning blood tests for early cancer detection

Amadix showcased non-invasive blood-based diagnostic tests that combine multiple signal modalities with machine learning to detect cancer earlier. The company credited EIC support and EuroQuity matchmaking with enabling introductions to international investors and opportunities to refine fundraising materials.

Amadix CEO Rocío Arroyo said the collaboration with EIC and EuroQuity helped them pitch to the right investors and connect with pharma and diagnostics partners that can accelerate commercialization and market access.

Investor perspective from F-Prime

Anastasiya Sybirna, Senior Associate at F-Prime Capital, said the quality of European startups is high and that EIC and Bpifrance fill a gap in early-stage funding. She welcomed additional programmes for scaling, noting a persistent gap in Europe between early-stage grant and seed support and later-stage scale-up capital.

Her remarks reflect a common investor view. Public programmes such as the EIC can de-risk early technology development. Yet private follow-on capital, cross-border syndication and the time required for clinical validation remain the constraints that will determine whether high meeting counts translate into investment rounds and product launches.

Full list of presenting companies

EIC Investment Readiness and Outreach Programme and EuroQuity collaboration

The Investor Day was organised under the EIC Investment Readiness and Outreach Programme which is part of the EIC Business Acceleration Services. Its stated aim is to boost investor readiness among EIC Accelerator beneficiaries and to connect them to relevant investors through ePitchings and Investor Days. EuroQuity is Bpifrance's matchmaking platform that helps European SMEs and startups access investors and business partners through curated e-communities and credentialing tools.

Implications and critical considerations

Investor Days are valuable for exposure and initial contact. The EIC event demonstrated the pipeline of Europe’s health deep tech and medtech companies and the active interest of a broad set of investors. However, several structural challenges will determine the longer term impact of these encounters.

First, clinical and regulatory timelines in diagnostics, therapeutics and medical devices are long. Raising seed or Series A capital after early validation is only the first step. Second, Europe still needs more scale-up capital and cross-border syndication to fund late-stage clinical programmes and commercial launches. Third, there is often limited transparency on actual conversion rates from meetings to investment which makes it hard to quantify the return on organiser efforts.

Policymakers and programme operators can improve impact by publishing follow-on metrics, by supporting investor syndication mechanisms and by sustaining public-private co-investment vehicles that bridge the gap to commercial investors. Promoters should also track whether introductions lead to term sheets, partnerships or trials rather than stopping at meeting counts.

Next steps and staying informed

The EIC Business Acceleration Services offers an EIC BAS newsletter to circulate open calls, success stories and partner opportunities. Founders and investors who want to follow future investor readiness activities can subscribe to that channel or engage with EuroQuity for matchmaking services.

Disclaimer: The information reported reflects the EIC announcement and public statements made by participating companies and investors at the event. Meeting counts and declared impacts do not constitute evidence of completed financings or regulatory approvals. Outcomes will depend on further diligence, data and capital mobilisation.